



## Hemangioli

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
II/0025	B.I.z - Quality change - Active substance - Other variation	12/12/2024	n/a		
PSUSA/10250 /202404	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	28/11/2024	n/a		PRAC Recommendation - maintenance

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



T/0023	Transfer of Marketing Authorisation	14/12/2022	10/01/2023	SmPC, Labelling and PL	
IA/0022	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	26/04/2022	n/a		
PSUSA/10250 /202104	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	13/01/2022	n/a		PRAC Recommendation - maintenance
II/0019	Update of section 4.4 of the SmPC to amend the existing warning on hypoglycaemia and of the Package Leaflet to amend the existing warnings on hypotension/bradycardia and hypoglycaemia following the completion of a Drug Utilisation Study (DUS) performed in Germany and France to evaluate off-label use and effectiveness of RMM in a real-life clinical setting (MEA 002); the Annex II to the Opinion is updated in accordance. In addition, editorial amendments are made to section 4.4 of the SmPC and to the Package Leaflet. The RMP version 3.5 has also been agreed.  C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	28/11/2019	18/11/2020	SmPC and PL	Propranolol can aggravate hypoglycaemia in children, especially during fasting period (e.g. poor oral food intake, infection, vomiting), when glucose demands are increased (cold, stress, infections), or in case of overdose. Prescribers should inform carers/parents on the risk of serious hypoglycaemia that remains equally prominent throughout the whole treatment period and emphasize the need to respect the dosing recommendations. Carers should be provided guidance on how to recognise the clinical signs of hypoglycaemia in order to immediately treat and prevent life-threatening situations, contact a doctor or go straight to hospital, and discontinue the treatment
PSUSA/10250 /201904	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	31/10/2019	n/a		PRAC Recommendation - maintenance
R/0018	Renewal of the marketing authorisation.	15/11/2018	15/01/2019	SmPC, Annex	

				II, Labelling and PL	
PSUSA/10250/201804	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	15/11/2018	11/01/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/10250/201804.
IA/0016	A.7 - Administrative change - Deletion of manufacturing sites	24/07/2018	n/a		
IAIN/0015	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	04/07/2018	n/a		
IA/0014	A.7 - Administrative change - Deletion of manufacturing sites	23/05/2018	15/01/2019	Annex II and PL	
N/0013	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/03/2018	15/01/2019	Labelling	
PSUSA/10250/201704	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	30/11/2017	n/a		PRAC Recommendation - maintenance
PSUSA/10250/201604	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	01/12/2016	n/a		PRAC Recommendation - maintenance
IAIN/0011	A.1 - Administrative change - Change in the name and/or address of the MAH	25/10/2016	n/a		
PSUSA/10250/201510	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	13/05/2016	n/a		PRAC Recommendation - maintenance

IB/0008	B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms	07/01/2016	n/a		
IB/0007	B.II.d.2.z - Change in test procedure for the finished product - Other variation	07/01/2016	n/a		
II/0004	B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF	26/11/2015	n/a		
PSUSA/10250/201504	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	06/11/2015	n/a		PRAC Recommendation - maintenance
PSUSA/10250/201410	Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)	07/05/2015	n/a		PRAC Recommendation - maintenance
IA/0005	B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold	30/04/2015	n/a		
II/0002	Update of section 4.8 of the SmPC to reflect the number of studies and the number of patients included in the safety database analysed, following completion of 2 safety studies one of which to investigate long term effects including effect on growth.  C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance	25/09/2014	03/07/2015	SmPC	The MAH has submitted the updated efficacy and safety report of the pivotal study 201 as well as the results of a small study conducted in France (study 301). The provided data were fully in agreement with the primary analysis and they not change the overall benefit-risk balance of Hemangirol in the authorised indication. This update did not lead to a change in the frequency or in the list of adverse events.

	data				
IB/0001/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p> <p>B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p>	10/07/2014	03/07/2015	SmPC, Annex II, Labelling and PL	